tiprankstipranks
Gilead Sciences (DE:GIS)
NASDAQ:GIS
Germany Market
GIS
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (GIS) Stock Forecast & Price Target

11 Followers
See the Price Targets and Ratings of:

GIS Analyst Ratings

Strong Buy
22Ratings
Strong Buy
19 Buy
3 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GIS Stock 12 Month Forecast

Average Price Target

€140.33
▲(20.02% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is €140.33 with a high forecast of €157.51 and a low forecast of €106.76. The average price target represents a 20.02% change from the last price of €116.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"90":"€90","107":"€107","124":"€124","141":"€141","158":"€158"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157.5089784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€157.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.3303675978947,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€140.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.75608536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€106.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[90,107,124,141,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.741,115.26161372307692,118.78222744615384,122.30284116923076,125.8234548923077,129.3440686153846,132.86468233846153,136.38529606153844,139.90590978461537,143.4265235076923,146.94713723076921,150.46775095384615,153.98836467692308,{"y":157.5089784,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.741,113.94018212291498,116.13936424582995,118.33854636874493,120.5377284916599,122.73691061457488,124.93609273748986,127.13527486040485,129.33445698331982,131.5336391062348,133.73282122914978,135.93200335206475,138.13118547497973,{"y":140.3303675978947,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.741,111.35754502769231,110.97409005538462,110.59063508307692,110.20718011076923,109.82372513846154,109.44027016615385,109.05681519384615,108.67336022153846,108.28990524923077,107.90645027692308,107.52299530461538,107.13954033230769,{"y":106.75608536,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.317,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.959,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.786,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.409,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.289,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.372,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.983,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.149,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.498,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.808,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.622,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.741,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€157.51Average Price Target€140.33Lowest Price Target€106.76
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on DE:GIS
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€135.63
Buy
16.00%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (NASDAQ: GALT) and Gilead Sciences (NASDAQ: GILD)
Scotiabank Analyst forecast on DE:GIS
Louise Chen
Scotiabank
Scotiabank
€154.88
Buy
32.47%
Upside
Reiterated
06/18/26
Gilead Sciences (GILD) Gets a Buy from Scotiabank
Citi Analyst forecast on DE:GIS
Geoff Meacham
Citi
Citi
€144.38
Buy
23.49%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Truist Financial Analyst forecast on DE:GIS
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
Needham Analyst forecast on DE:GIS
Joseph Stringer
Needham
Needham
€148.76
Buy
27.23%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on DE:GIS
Salim Syed
Mizuho Securities
Mizuho Securities
€148.76
Buy
27.23%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Wells Fargo Analyst forecast on DE:GIS
Mohit Bansal
Wells Fargo
Wells Fargo
€161.88→€144.38
Buy
23.49%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on DE:GIS
Courtney Breen
Bernstein
Bernstein
€140.01
Buy
19.75%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
RBC Capital Analyst forecast on DE:GIS
Brian Abrahams
RBC Capital
RBC Capital
€106.76
Hold
-8.69%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Hinge Health, Inc. Class A (NYSE: HNGE) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
J.P. Morgan Analyst forecast on DE:GIS
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/08/26
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
Morgan Stanley Analyst forecast on DE:GIS
Terence Flynn
Morgan Stanley
Morgan Stanley
€147.01
Buy
25.73%
Upside
Reiterated
06/04/26
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
Bank of America Securities Analyst forecast on DE:GIS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€141.76
Buy
21.24%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Gilead Sciences (NASDAQ: GILD) and Celcuity (NASDAQ: CELC)
Jefferies Analyst forecast on DE:GIS
Akash Tewari
Jefferies
Jefferies
€157.51
Buy
34.72%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on DE:GIS
Michael Okunewitch
Maxim Group
Maxim Group
€144.38
Buy
23.49%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Argus Research Analyst forecast on DE:GIS
Unknown Analyst
Argus Research
Not Ranked
Argus Research
€144.38
Buy
23.49%
Upside
Reiterated
05/15/26
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on DE:GIS
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€135.63
Buy
16.00%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (NASDAQ: GALT) and Gilead Sciences (NASDAQ: GILD)
Scotiabank Analyst forecast on DE:GIS
Louise Chen
Scotiabank
Scotiabank
€154.88
Buy
32.47%
Upside
Reiterated
06/18/26
Gilead Sciences (GILD) Gets a Buy from Scotiabank
Citi Analyst forecast on DE:GIS
Geoff Meacham
Citi
Citi
€144.38
Buy
23.49%
Upside
Reiterated
06/17/26
Gilead Sciences (GILD) Receives a Buy from Citi
Truist Financial Analyst forecast on DE:GIS
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/16/26
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD)
Needham Analyst forecast on DE:GIS
Joseph Stringer
Needham
Needham
€148.76
Buy
27.23%
Upside
Assigned
06/12/26
Gilead Sciences (GILD) Gets a Buy from Needham
Mizuho Securities Analyst forecast on DE:GIS
Salim Syed
Mizuho Securities
Mizuho Securities
€148.76
Buy
27.23%
Upside
Reiterated
06/12/26
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Wells Fargo Analyst forecast on DE:GIS
Mohit Bansal
Wells Fargo
Wells Fargo
€161.88→€144.38
Buy
23.49%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA) and Gilead Sciences (NASDAQ: GILD)
Bernstein Analyst forecast on DE:GIS
Courtney Breen
Bernstein
Bernstein
€140.01
Buy
19.75%
Upside
Reiterated
06/09/26
Gilead Sciences (GILD) Gets a Buy from Bernstein
RBC Capital Analyst forecast on DE:GIS
Brian Abrahams
RBC Capital
RBC Capital
€106.76
Hold
-8.69%
Downside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Hinge Health, Inc. Class A (NYSE: HNGE) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
J.P. Morgan Analyst forecast on DE:GIS
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/08/26
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
Morgan Stanley Analyst forecast on DE:GIS
Terence Flynn
Morgan Stanley
Morgan Stanley
€147.01
Buy
25.73%
Upside
Reiterated
06/04/26
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
Bank of America Securities Analyst forecast on DE:GIS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€141.76
Buy
21.24%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Gilead Sciences (NASDAQ: GILD) and Celcuity (NASDAQ: CELC)
Jefferies Analyst forecast on DE:GIS
Akash Tewari
Jefferies
Jefferies
€157.51
Buy
34.72%
Upside
Reiterated
05/22/26
Jefferies Remains a Buy on Gilead Sciences (GILD)
Maxim Group Analyst forecast on DE:GIS
Michael Okunewitch
Maxim Group
Maxim Group
€144.38
Buy
23.49%
Upside
Upgraded
05/20/26
Gilead upgraded to Buy from Hold at MaximGilead upgraded to Buy from Hold at Maxim
Argus Research Analyst forecast on DE:GIS
Unknown Analyst
Argus Research
Not Ranked
Argus Research
€144.38
Buy
23.49%
Upside
Reiterated
05/15/26
Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Tyler Van BurenTD Cowen
Success Rate
24/31 ratings generated profit
77%
Average Return
+7.37%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 77.42% of your transactions generating a profit, with an average return of +7.37% per trade.
1 Year
Tyler Van BurenTD Cowen
Success Rate
26/31 ratings generated profit
84%
Average Return
+26.92%
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 83.87% of your transactions generating a profit, with an average return of +26.92% per trade.
2 Years
Chris SchottJ.P. Morgan
Success Rate
21/23 ratings generated profit
91%
Average Return
+39.70%
Copying Chris Schott's trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +39.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GIS Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
53
50
48
41
56
Hold
10
10
13
12
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
63
60
61
53
69
In the current month, GIS has received 56 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. GIS average Analyst price target in the past 3 months is 140.33.
Each month's total comprises the sum of three months' worth of ratings.

GIS Financial Forecast

GIS Earnings Forecast

Next quarter’s earnings estimate for GIS is -€6.38 with a range of -€6.91 to -€5.58. The previous quarter’s EPS was €1.77. GIS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GIS has Performed in-line its overall industry.
Next quarter’s earnings estimate for GIS is -€6.38 with a range of -€6.91 to -€5.58. The previous quarter’s EPS was €1.77. GIS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GIS has Performed in-line its overall industry.

GIS Sales Forecast

Next quarter’s sales forecast for GIS is €6.46B with a range of €6.29B to €6.67B. The previous quarter’s sales results were €6.08B. GIS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GIS has Performed in-line its overall industry.
Next quarter’s sales forecast for GIS is €6.46B with a range of €6.29B to €6.67B. The previous quarter’s sales results were €6.08B. GIS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GIS has Performed in-line its overall industry.

GIS Stock Forecast FAQ

What is DE:GIS’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 140.33.
    What is DE:GIS’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 20.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Gilead Sciences a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy, which is based on 19 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s share price target?
            The average share price target for Gilead Sciences is 140.33. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €157.51 ,and the lowest forecast is €106.76. The average share price target represents 20.02% Increase from the current price of €116.92.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Gilead Sciences?
                To buy shares of DE:GIS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.